National Bank of Canada
CGON icon

National Bank of Canada’s CG Oncology CGON Stock Holding History

National Bank of Canada’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213 Buy
+3
New +$196 ﹤0.01% 2957

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

National Bank of Canada's CGON Position: Q2 2026 in Review

National Bank of Canada opened a new position in CG Oncology (CGON) in Q2 2026: 3 shares worth $213. The stake represents ﹤0.01% of the portfolio and ranks #2957 among its holdings.

227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • National Bank of Canada held 3 shares of CG Oncology worth $213 as of Q2 2026.
  • CG Oncology was a new National Bank of Canada position in Q2 2026.
  • CG Oncology made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2957 holding.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.